CALCIMEDICA INC (CALC) Stock Price, Forecast & Analysis
NASDAQ:CALC • US38942Q2021
CALC Key Statistics, Chart & Performance
The current stock price of CALC is 0.55 USD. In the past month the price decreased by -90.18%. In the past year, price decreased by -76.6%.
CALC Technical Analysis
CALC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CALC. CALC may be in some trouble as it scores bad on both profitability and health.
CALC Financial Highlights
Over the last trailing twelve months CALC reported a non-GAAP Earnings per Share(EPS) of -1.66. The EPS decreased by -53.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -154.63% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CALC Forecast & Estimates
10 analysts have analysed CALC and the average price target is 16.66 USD. This implies a price increase of 2929.09% is expected in the next year compared to the current price of 0.55.
CALC Ownership
CALC Latest News, Press Relases and Analysis
CALC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.41 | 979.461B | ||
| JNJ | JOHNSON & JOHNSON | 21.03 | 586.255B | ||
| MRK | MERCK & CO. INC. | 22.49 | 301.739B | ||
| PFE | PFIZER INC | 9.11 | 155.618B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.82 | 122.858B | ||
| ZTS | ZOETIS INC | 18.8 | 55.333B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.74 | 26.212B | ||
| VTRS | VIATRIS INC | 6.35 | 18.129B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.7 | 12.352B | ||
| AXSM | AXSOME THERAPEUTICS INC | 225.58 | 9.24B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CALC
Company Profile
CalciMedica, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2020-09-25. The firm focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The firm's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The firm is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
Company Info
CALCIMEDICA INC
505 Coast Boulevard South, Suite 307
La Jolla CALIFORNIA US
Employees: 14
Phone: 18589525500
CALCIMEDICA INC / CALC FAQ
What does CALCIMEDICA INC do?
CalciMedica, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2020-09-25. The firm focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The firm's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The firm is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
Can you provide the latest stock price for CALCIMEDICA INC?
The current stock price of CALC is 0.55 USD. The price decreased by -10.23% in the last trading session.
Does CALC stock pay dividends?
CALC does not pay a dividend.
What is the ChartMill rating of CALCIMEDICA INC stock?
CALC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the ownership structure of CALCIMEDICA INC (CALC)?
You can find the ownership structure of CALCIMEDICA INC (CALC) on the Ownership tab.